Koa Health, a digital mental healthcare provider, has entered into a strategic collaboration with Janssen Pharmaceutica NV, part of products giant Johnson & Johnson.
Through the collaboration, Koa Health will work with Janssen scientists to research the delivery of digital cognitive behavioural therapy (dCBT) for treatment resistant major depressive disorder (MDD) patients, in conjunction with pharmacological treatments.
The agreement was facilitated by Johnson & Johnson Innovation, the group’s collaborative arm.
As part of the programme, Koa Health and Janssen will perform a US multi-site feasibility study to assess the use of dCBT in conjunction with a pharmacological treatment in patients with treatment-resistant depression (TRD).
Oliver Harrison, CEO Koa Health says: “Our goal at Koa Health is to provide easy access to a range of digital mental health solutions which meet the mental health needs of every individual and help them to flourish.
“Treatment-resistant depression and major depressive disorder can be debilitating conditions for patients, having a serious impact on the way they think, feel and act. Patients often experience persistent feelings of sadness or despair and have difficulty with everyday life.
“By trialling the use of digital cognitive behavioural therapy, specifically designed for TRD patients, we aim to improve treatment outcomes in this difficult to treat patient population.”
Depression is the condition most frequently associated with suicide and the average cost of healthcare for a patient with TRD is up to 2.8 times higher than for patients with non-TRD or non-MDD.
The collaboration between Janssen and Koa Health aims to provide vital research into an area of mental health for patients that have endured long-term suffering.
Koa Health is a digital mental healthcare provider that offers integrated mental health solutions, covering the waterfront from improving wellbeing to supporting treatment for a range of common mental disorders.
Sign up to our newsletter